EH09-043: A Multi-Phase Study of Active Surveillance for Men with Clinical Stage T1c or T2a Localized Prostate Cancer
Aims: The purpose of this study is to identify which patients can wait for curative therapy (such as surgery, radiation or hormonal treatment) and to investigate new and better ways to identify disease progression.
Diagnosis: Stage T1c or T2a Localized Prostate Cancer
Principal Investigator: Charles Brendler, MD
IRB Approval Number: EH09-043
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact study coordinator Sarah Rabbitt at 847.570.1681
Open to Enrollment: Yes

REASSURE: Radium-223 Alpha Emitter Agent in Non-Interventional Safety Study in Metastatic Castrate Presistant Prostate Cancer Population for Long-Term Evaluation 
Aims:The purpose of the study is to evaluate the short and long term safety profile of Radium-223 under routine practice conditions. The study was initiated and is financed by Bayer HealthCare Pharmaceuticals Inc. This includes payment of a reimbursement to your doctor and his/her team for the cost of the study. Bayer HealthCare Pharmaceuticals, Inc. may hire contract service providers to support in the performance of the study.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH14-261
Sponsor:Bayer HealthCare Pharmaceuticals, Inc.
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

3104007: A Multinational, Randomized, Double-Blind, Placebo-Controlled, Phase III Efficacy and Safety Study of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostrate Cancer
Aims: The purpose of this study is to assess the safety and effectiveness of the study drug ODM-201 compared to placebo (a dummy medication that looks like the real medication but has no active ingredients) in men with prostate cancer who have recurrence of disease despite hormone therapy and no evidence of metastasis (no evidence that cancer has spread to other areas of the body). The study treatment will be given in conjunction with your current hormonal treatment, if you have been prescribed such treatment. ODM-201 is a new investigational drug being developed for men who have no evidence that their cancer has spread to other areas of the body, but who have high risk of their cancer spreading.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH14-156
Sponsor: Orion Corporation, Orion Pharma
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

UC12-0109: A Randomized Gene Fusion Statefied Phase II Trial of Abiraterone with or without ABT-888 for Patients with Metastatic Castration Resistant Prostate Cancer
Aims: ABT-888 (Veliparib) is a drug that has been shown to inhibit the expression of enzymes that are found in tumor cells. The purpose of this study is to look at the role of a specific combination of genes known as "ETS gene fusion." Researchers will try to determine if this combinatoin of genes can predict how a patient will respond to the use of abiraterone along with prednisone, or the use of abiraterone along with prednisone plus the investigatoinal drug ABT-888. The investigators will also look at whether adding ABT-888 to abiraterone and prednisone is more effective when compared to abiraterone and prednisone without ABT-888.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH13-057
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

UC11-0709: A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men with Castrate Resistant Prostate Cancer
Aims:  Abiraterone acetate is an FDA approved treatment for prostate cancer patients who have progressed after receiving prior docetaxel chemotherapy. The current FDA labeling for abiraterone indicates that the drug be taken while fasting. The primary objective of this trial is to compare the effect of a reduced dose of abiraterone acetate taken with food to the full, standard daily dose in the fasting state.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH12-369
Sponsor: The University of Chicago
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment:
Yes

AbiCure: A Phase 2, Randomized, 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degaralix Alone for Patients with Prostrate Cancer with a Rising PSA or a Rising PSA or a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Aims:  The FDA has approved the oral drug abiraterone acetate (Zytiga ®) in combination with prednisone (a steroid) to treat patients with metastatic castration-resistant prostate cancer. Degarelix (Firmagon ®), a testosterone lowering agent given as a monthly injection, is FDA approved for the treatment of patients with advanced prostate cancer.  The purpose of this study is to evaluate abiraterone acetate and prednisone in combination with degarelix as a possible treatment for PSA recurrent prostate cancer as compared to abiraterone acetate plus prednisone alone and degarelix alone.
Diagnosis: Prostate Cancer
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH13-147
Sponsor: Memorial Sloan Kettering Cancer Center
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

SPORE: Tissue, Blood, and Urine Banking for the Robert H. Lurie Comprehensive Cancer Center Prostate Tissue Bank
Aims: This study involves the banking (storing) of prostate tissue, blood and urine. Information from the patient's medical records and treatment will be followed for an indefinite amount of time up to 75 years or more. The purpose of the study is to enable cancer researchers and other investigators attain a better understanding of the development of prostate cancer, its treatment, prevention, and cure.
Diagnosis: Prostate
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH01-129
Sponsor: Robert H. Lurie Comprehensive Cancer Center
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

S0931: EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study
Aims: The current standard treatment after surgery for kidney cancer is careful monitoring with no immediate treatment. The purpose of this study is to see whether treatment with everolimus after surgery for kidney cancer will increase the time without cancer returning. 
Diagnosis: Renal Cancer
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH14-033
Sponsor: Southwest Oncology Group (SWOG)
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
Aims: The purpose of this study is to find out what effects (good and/or bad) there are to adding the new investigational drug TAK-700 to standard hormone therapy for prostate cancer as compared to the standard hormone therapy alone. 
Diagnosis: Prostate Cancer
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH14-055
Sponsor: Southwest Oncology Group (SWOG)
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

A031201: Phase III Trial of Enzalutamine Vs. Enzalutamine, Abiraterone, and Prednisone for Castration Restraint Metastatic Prostate Cancer
Aims: The purpose of this study is to compare the effects, good and/or bad, of abiraterone, prednisone, and enzalutamide with enzalutamide alone on you and your prostate cancer to find out which is better. Doctors are uncertain about what is the best way to treat castration resistant prostate cancer (CRPC). In this study, you will get either the combination of abiraterone, prednisone, and enzalutamide or enzalutamide alone. Abiraterone and enzalutamide are both hormonal agents approved by the Food and Drug Administration for patients with castration-resistant metastatic disease. Each drug works in a different way to block hormones. Abiraterone and enzalutamide are both highly active drugs in men with CRPC. Abiraterone has recently received FDA approval for patients who have not received chemotherapy, such as you. In previous studies, enzalutamide appeared to be at least as active as abiraterone in patients with CRPC who have received prior chemotherapy, and it may be at least as active in patients who have not received chemotherapy. 
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH14-180
Sponsor: Alliance
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

UC13-0540: Afatinib in Advanced Refractory Urothelial Cancer
Aims: The purpose of this study is find out what effects, good and/or bad, the experimental drug BIBW 2992 (also called afatinib) has on you and your advanced urothelial cancer. This drug is experimental and has not been approved by the Food and Drug Administration (FDA) for use in the treatment of urothelial cancer. BIBW 2992 belongs to a group of drugs that can affect the function of special proteins (chemicals in the body) called growth factor receptors that are found on the surface of many cancer cells. A receptor is like a lock to which a matching drug fits like a key. The particular growth factors that BIBW 2992 will fit are called EGF (Epidermal Growth Factor) and HER2 (Human Epidermal Growth Factor Receptor). When these receptors are stimulated, the growth of the cancer cells with the receptors is accelerated. In contrast, BIBW 2992 is thought to turn off the function of the EGF and HER2 receptors, leading to slowing of growth and even causing some of these cancer cells to die. 
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH14-083
Sponsor: The University of Chicago
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

A4061070: Metastatic Renal Cell Cancer Registry (MaRCC Registry)
Aims: The main goal of this study is to understand the treatment of patients with metastatic kidney cancer in routine real-world clinical practice in the United States (US), including both community and academic treatment settings. The study will collect and assess information, related to how your kidney cancer is being treated by your doctor.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH14-247
Sponsor: Pfizer, Inc.
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

× Alternate Text